StockNews.AI
AZN
StockNews.AI
172 days

Neurofibromatoses Therapeutics Competitive Landscape Report 2024: Pipeline Holds 35 Molecules - Currently Only 1 Approved Innovator Drug, AstraZeneca's (Koselugo/Coselugo) Selumetinib Sulfate

1. AstraZeneca's Koselugo is the only approved drug for Neurofibromatosis type 1. 2. 986,000 Neurofibromatosis cases are expected in 2024 across the covered countries. 3. The neurofibromatosis pipeline contains 35 molecules, with two in pre-registration. 4. 106 clinical trials for Neurofibromatosis have been conducted in the past decade. 5. Partnerships are common among North America, Europe, and Asia-Pacific for drug development.

5m saved
Insight
Article

FAQ

Why Bullish?

AstraZeneca's sole market presence for Neurofibromatosis provides a competitive edge. Historical data shows that exclusive drugs often see price growth following approval and market establishment.

How important is it?

The article discusses ongoing and future treatments for an illness with high patient prevalence, directly benefiting AZN’s operations.

Why Long Term?

As more patients are diagnosed and pipelines mature, AZN's long-term presence could strengthen. The growth in new treatments can also stabilize market position over the coming years.

Related Companies

REGNMRNAJNJ
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatoses: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the current and future competitive landscape in Nurofibromatoses therapeutics. In 2024, more than 986,000 diagnosed prevalent cases of Nurofibromatoses are anticipated in the 16 countries covered in the analyst's epidemiology forecast. Currently, only one approved innovator drug, AstraZeneca's (Koselugo/Coselugo) selumetinib sulfate, is available on the market for the treatment of pediatric patients ages two years and older with NF type 1. The NF pipeline holds 35 molecules, with two assets in the pre-registration stage. Over the past decade, 106 clinical trials have been conducted in NF. The highest number of studies were initiated in 2019 with 13 trials, followed by 2020 and 2021 with 12 trials each. In the past decade, partnerships were the most common deal type for North America, Europe, and Asia-Pacific (APAC).Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.Develop business strategies by understanding the trends shaping and driving the Nurofibromatoses market.Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Nurofibromatoses market in the future.Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered:1 Table of Contents1 Preface1.1 Contents1.2 Report Scope1.3 List of Tables and Figures1.4 Abbreviations2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market Catalysts11 AppendixFor more information about this report visit https://www.researchandmarkets.com/r/74pjqk About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News